ATLAS Biolabs achieves Roche NimbleGen Certification for solution-based SeqCap EZ enrichment

Madison, WI (US), (PresseBox) - Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) announces that ATLAS Biolabs GmbH, located in Berlin, Germany, has passed the certification process to qualify as a Roche NimbleGen Certified Service Provider (CSP) for SeqCap EZ enrichment.

Roche NimbleGen recently launched a new addition to the SeqCap EZ product portfolio with SeqCap EZ Choice Libraries for enrichment of custom regions of interest in a single test tube. This new technology is an ideal solution in the research market for the disease-associated regions (DAR) and, in addition to our SeqCap EZ Exome library, is also of tremendous interest to the next-generation sequencing community. NimbleGen sequence capture technologies will be featured in an upcoming workshop offered by Roche and ATLAS Biolabs. For more information on this exciting workshop, please visit www.nimblegen.com/akademie.

Having passed a rigorous certification test plan to achieve precise experimental standards, ATLAS Biolabs GmbH has obtained and expanded official certification as a Roche NimbleGen Certified Service Provider. This marks the second time that a genomic service provider will join the Roche NimbleGen CSP Program for SeqCap EZ Exome in Europe. ATLAS will process customer gDNA samples for genomic enrichment, using the complete NimbleGen Sequence Capture Array and solution-based capture workflow. Enriched samples can then be analyzed on the long-read Roche GS FLX and GS Junior platforms as well as on short-read sequencing platforms.

"The new product combines the superior performance of NimbleGen Sequence Capture arrays with an easy-to-use, scalable workflow at a very attractive price. It is definitely an excellent solution for the targeted sequencing projects we are running at ATLAS," stated Prof. Dr. Peter Nürnberg, CEO of ATLAS Biolabs GmbH.

"Roche NimbleGen welcomes ATLAS Bioloabs as the first certified service provider for SeqCap EZ enrichment in Germany," said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc. "Researchers throughout the world have adopted SeqCap EZ enrichment as their target enrichment technology of choice due to its performance and scalability. We are excited to extend the high performance capabilities of SeqCap EZ Exome and SeqCap EZ Choice to the genomic community in Germany through ATLAS Biolabs."

For more information on Roche NimbleGen, please visit www.nimblegen.com

About ATLAS Biolabs GmbH

ATLAS Biolabs GmbH, with offices and laboratories in Berlin and Cologne, is a leading European service provider of several high-throughput microarray-based applications such as targeted genomic enrichment, genome-wide expression analysis, SNP analysis, and CGH analysis, followed by high performance data processing and bioinformatics. The company's main mission is to deliver consistent, high-quality genomic services to their customers through the use of streamlined, formalized business processes. ATLAS Biolabs' commitment to quality includes the certification according to DIN EN ISO 9001:2008 and EN ISO 13485:2003 + AC:2009. Customers of ATLAS Biolabs include academic institutions, pharmaceutical and biotechnological enterprises as well as clinicians and registered doctors in and outside of Germany. For more information please access www.atlas-biolabs.com.

For life science research only. Not for use in diagnostic procedures.

454, 454 LIFE SCIENCES, GS FLX TITANIUM, 454 SEQUENCING, GS FLX, GS JUNIOR, SEQCAP, and NIMBLEGEN are trademarks of Roche.

Roche Diagnostics Deutschland GmbH

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.